In December 1997, she took the last spot in a clinical trial. But there were risks and uncertainties. Brooke relapsed and eventually was put on the drug, which gained FDA approval for use in children in May 1999. In retrospect, Brooke is glad she participated. In some cases, healthy youngsters are study subjects, raising questions about whether they are being exposed to risks without possible benefits.
Some studies pay children to enroll.
This escapes federal regulation. Although the money is typically designated to cover expenses, it may include profits.